Abstract
The worldwide dissemination of ‹multi-drug resistant› (MDR) pathogens has severely reduced the efficacy of our antibiotic arsenal and increased the frequency of therapeutic failure. MDR bacteria over-express efflux pumps and this active mechanism can extrude all classes of antibiotics from the cell.
It is necessary to clearly decipher the genetic, structural and functional aspects of this transport system in order to combat this polyselective mechanism. By understanding how efflux pumps work we may be able to develop a new group of antibacterial agents, collectively termed efflux reversals, including membrane permeabilisers, efflux pump inhibitors and flux-competitive agents, specific blockers, energy poisons, etc. Several chemical families of efflux pump inhibitors have been described and characterized. Among them several inhibitor compounds demonstrate efficient blocking of the efflux pump activity involved in the MDR phenotype as observed in many Gram-negative clinical isolates. This new family of molecules represents the first antibacterial class of compound specifically targeting active transport in the bacterial cell.
Keywords: Antibiotic, antibacterial agent, bacterial transporter, chemosensitizer, efflux pump, efflux pump inhibitor, drug transporter, Gram negative, bacteria, genetic regulation cascade, membrane permeability
Current Medicinal Chemistry
Title: An Original Deal for New Molecule: Reversal of Efflux Pump Activity, A Rational Strategy to Combat Gram-Negative Resistant Bacteria
Volume: 18 Issue: 19
Author(s): J.-M. Pages, L. Amaral and S. Fanning
Affiliation:
Keywords: Antibiotic, antibacterial agent, bacterial transporter, chemosensitizer, efflux pump, efflux pump inhibitor, drug transporter, Gram negative, bacteria, genetic regulation cascade, membrane permeability
Abstract: The worldwide dissemination of ‹multi-drug resistant› (MDR) pathogens has severely reduced the efficacy of our antibiotic arsenal and increased the frequency of therapeutic failure. MDR bacteria over-express efflux pumps and this active mechanism can extrude all classes of antibiotics from the cell.
It is necessary to clearly decipher the genetic, structural and functional aspects of this transport system in order to combat this polyselective mechanism. By understanding how efflux pumps work we may be able to develop a new group of antibacterial agents, collectively termed efflux reversals, including membrane permeabilisers, efflux pump inhibitors and flux-competitive agents, specific blockers, energy poisons, etc. Several chemical families of efflux pump inhibitors have been described and characterized. Among them several inhibitor compounds demonstrate efficient blocking of the efflux pump activity involved in the MDR phenotype as observed in many Gram-negative clinical isolates. This new family of molecules represents the first antibacterial class of compound specifically targeting active transport in the bacterial cell.
Export Options
About this article
Cite this article as:
Pages J.-M., Amaral L. and Fanning S., An Original Deal for New Molecule: Reversal of Efflux Pump Activity, A Rational Strategy to Combat Gram-Negative Resistant Bacteria, Current Medicinal Chemistry 2011; 18 (19) . https://dx.doi.org/10.2174/092986711796150469
DOI https://dx.doi.org/10.2174/092986711796150469 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses COVID-19 Pandemic: Age and Temperature Related Effects
Coronaviruses Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones
Anti-Infective Agents in Medicinal Chemistry Solution-Phase Parallel Synthesis of an Isoflavone Library for the Discovery of Novel Antigiardial Agents
Combinatorial Chemistry & High Throughput Screening Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Severe Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research
Current Neurovascular Research Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy Antibiotic Resistance and Microbiota Response
Current Pharmaceutical Design Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry Epigenetic Programming of Adipose Tissue in the Progeny of Obese Dams
Current Genomics Coumarin-based Scaffold as α-glucosidase Inhibitory Activity: Implication for the Development of Potent Antidiabetic Agents
Mini-Reviews in Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Relationship Between Virulence Factors and Outcome of Ventilator-Associated Pneumonia Related to Pseudomonas aeruginosa
Current Respiratory Medicine Reviews Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Human Amnion-Derived Cells: Prospects for the Treatment of Lung Diseases
Current Stem Cell Research & Therapy Non-Peptidic HIV Protease Inhibitors
Current Topics in Medicinal Chemistry The Effect of Plant Metabolites on Coronaviruses: A Comprehensive Review Focusing on their IC<sub>50</sub> Values and Molecular Docking Scores
Mini-Reviews in Medicinal Chemistry First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Letters in Drug Design & Discovery